U.S. Markets closed

Clovis Oncology Announces Rubraca®▼ (rucaparib) Now Available for Women with Relapsed Ovarian Cancer in England Through the Cancer Drugs Fund

BOULDER, Colo.--(BUSINESS WIRE)--

Clovis Oncology, Inc. (CLVS) today announced that the National Institute for Health and Care Excellence (NICE) has recommended that women with relapsed ovarian cancer in England have access to rucaparib through the Cancer Drugs Fund (CDF).1 Rucaparib is available for use within the CDF as an option for the maintenance treatment of relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy in adults, based on the conditions outlined in the managed access agreement.

"Ovacome welcomes the availability of rucaparib via the CDF as an option for maintenance treatment of platinum-sensitive relapsed high grade serous epithelial ovarian cancer regardless of BRCA status or line of treatment in the relapsed maintenance setting,” said Victoria Clare, CEO of Ovacome, a United Kingdom ovarian cancer charity focused on providing support to anyone affected by ovarian cancer. “It is vital that the expansion of available maintenance options continues as maintenance treatments extend the time between chemotherapies. Many women with relapsed ovarian cancer know that they are facing a future of managing their disease as a chronic illness.”

“For too long ovarian cancer treatment options beyond chemotherapy or surgery have been limited, and today’s announcement means that women with ovarian cancer have more choice in their treatment than ever before,” said Annwen Jones, Chief Executive of Target Ovarian Cancer, a United Kingdom ovarian cancer charity. “Target Ovarian Cancer has long campaigned for better treatment for women with ovarian cancer and we are delighted to see this latest development.”

Approximately 6,400 women are diagnosed with ovarian cancer in the UK every year, which equates to roughly 17 every day.2 Despite advancements in treatment and care, more than 4,000 women still die each year from ovarian cancer in the UK.2 Of those treated with surgery and first line chemotherapy, approximately 70% of patients will relapse within the first three years.3

“Inclusion of rucaparib in the CDF as an option for maintenance treatment for patients with recurrent ovarian cancer responding to platinum-based therapy regardless of BRCA mutation status or line of treatment in the relapsed maintenance setting represents a much-needed treatment option for women with recurrent ovarian cancer,” said Professor Jonathan Ledermann, MD, Professor of Medical Oncology, UCL Cancer Institute and UCL Hospitals, London, global Principal Investigator for non-US sites in the ARIEL3 study. “I am pleased that the CDF recommendation includes access for the broad patient population evaluated in the ARIEL3 trial which demonstrated rucaparib to be effective in eligible patients, regardless of their BRCA mutation status, providing a clinically-meaningful median progression-free survival of more than one year across the entire population studied by independent radiological review. This represents a significant step in the effective management of relapsed ovarian cancer in the NHS in England.”

The European Union (EU) conditional marketing authorization is based on data from the pivotal Phase 3 ARIEL3 clinical trial. ARIEL3 successfully achieved its primary endpoint of extending investigator-assessed PFS versus placebo in all patients treated (intention-to-treat, or ITT), population, regardless of BRCA status (median 10.8 months vs 5.4 months).4,5 In addition, it successfully achieved the key secondary endpoint of extending PFS by independent radiological review versus placebo in all patients treated (ITT), regardless of BRCA status (median 13.7 months vs 5.4 months).5 The overall safety profile of rucaparib is based on data from 937 patients with ovarian cancer treated with rucaparib monotherapy in clinical trials.5

“We welcome NICE’s recommendation to make rucaparib available through the CDF to all eligible women in England who may potentially benefit from this important therapeutic option,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. “For women with recurrent ovarian cancer, access to new treatments that successfully demonstrate prolonged progression-free survival is essential in the fight against this deadly disease and central to Clovis Oncology’s mission to provide the right drug, to the right patient at the right time.”

About Rubraca® (rucaparib)

Rubraca is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 that is being developed in multiple tumor types, including ovarian and metastatic castration-resistant prostate cancer (mCRPC), as monotherapy, and in combination with other anti-cancer agents. Exploratory studies in other tumor types are also underway.

Rubraca® (rucaparib) European Union (EU) Conditional Marketing Authorization

Rubraca is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.

Rubraca is indicated as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with ≥ 2 prior lines of platinum-based chemotherapy, and who are unable to tolerate further platinum-based chemotherapy.

Summary Warnings, Precautions and Safety

Efficacy of Rubraca as treatment for relapsed or progressive EOC, FTC, or PPC has not been investigated in patients who have received prior treatment with a PARP inhibitor. Therefore, use in this patient population is not recommended.

The overall safety profile of rucaparib is based on data from 937 patients in clinical trials in ovarian cancer treated with rucaparib monotherapy. Adverse reactions occurring in ≥ 20% of patients receiving rucaparib were nausea, fatigue/asthenia, vomiting, anaemia, abdominal pain, dysgeusia, ALT elevations, AST elevations, decreased appetite, diarrhoea, thrombocytopenia and creatinine elevations. The majority of adverse reactions were mild to moderate (Grade 1 or 2).

The ≥ Grade 3 adverse reactions occurring in > 5% of patients were anaemia (23%), ALT elevations (10%), fatigue/asthenia (10%), neutropenia (8%), thrombocytopenia (6%), and nausea (5%). The only serious adverse reaction occurring in > 2% of patients was anaemia (5%).

Adverse reactions that most commonly led to dose reduction or interruption were anaemia (20%), fatigue/asthenia (18%), nausea (16%), thrombocytopenia (15%), and AST/ALT elevations (10%). Adverse reactions leading to permanent discontinuation occurred in 10% of patients, with thrombocytopenia, nausea, anaemia, and fatigue/asthenia being the most frequent adverse reactions leading to permanent discontinuation.

During treatment with rucaparib, events of myelosuppression (anaemia, neutropenia, thrombocytopenia) may be observed and are typically first observed after 8-10 weeks of treatment with rucaparib. These reactions are manageable with routine medical treatment and/or dose adjustment for more severe cases. Complete blood count testing prior to starting treatment with rucaparib and monthly thereafter, is advised. Patients should not start rucaparib until they have recovered from haematological toxicities caused by previous chemotherapy (≤ CTCAE Grade 1).

Myelodysplastic syndrome/acute myeloid leukaemia (MDS/AML), including cases with fatal outcome, have been reported in patients who received rucaparib. The duration of therapy with rucaparib in patients who developed MDS/AML varied from less than 1 month to approximately 28 months. If MDS/AML is suspected, the patient should be referred to a haematologist for further investigations, including bone marrow analysis and blood sampling for cytogenetics. If, following investigation for prolonged haematological toxicity, MDS/AML is confirmed, rucaparib should be discontinued.

Further information should be obtained from the Rucaparib Summary of Product Characteristics (SmPC) found here: https://www.medicines.org.uk/emc/product/10028/smpc.

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Side effects should be reported. See https://yellowcard.mhra.gov.uk for how to report side effects.

About Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, with additional office locations in the U.S. and Europe. Please visit www.clovisoncology.com for more information.

To the extent that statements contained in this press release are not descriptions of historical facts regarding Clovis Oncology, they are forward-looking statements reflecting the current beliefs and expectations of management. Examples of forward-looking statements contained in this press release include, among others, statements regarding our plans to launch Rubraca in additional European countries, including the United Kingdom, and to make Rubraca available to additional eligible patients. Such forward-looking statements involve substantial risks and uncertainties that could cause our future results, performance or achievements to differ significantly from that expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the market potential of Rubraca, including the performance of our sales and marketing efforts and the success of competing drugs and therapeutic approaches, the performance of our third-party manufacturers, our clinical development programs for our drug candidates and those of our partners, and actions by the FDA, the EMA or other regulatory authorities regarding data required to support drug applications and whether to accept or approve drug applications that may be filed, as well as their decisions regarding drug labeling, reimbursement and pricing. Clovis Oncology does not undertake to update or revise any forward-looking statements. A further description of risks and uncertainties can be found in Clovis Oncology’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its reports on Form 10-Q and Form 8-K.

References

  1. NICE final appraisal document (FAD) for Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer. Available at https://www.nice.org.uk/guidance/published?type=ta
  2. World Health Organization. GLOBOCAN: estimated cancer incidence, mortality and prevalence worldwide in 2018. Available at http://gco.iarc.fr/ Last accessed October 2019.
  3. Ledermann J, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(suppl 6):vi24–32.
  4. Coleman RL, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;390:1949–61.
  5. Summary of Product Characteristics Rubraca 200, 250, 300 mg film-coated tablets. Available at: https://www.ema.europa.eu/en/documents/product-information/rubraca-epar-product-information_en.pdf. Last accessed October 2019.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20191011005292/en/

  • What's the Average 401(k) Balance by Age?
    Business
    Investopedia

    What's the Average 401(k) Balance by Age?

    It can be hard to determine exactly how much you'll need for your own post-career days, but finding out how others are planning—or not—can offer a benchmark for setting goals and milestones. k) Plan Balances by Generation The good news is that Americans have been making an effort to save more. According to Fidelity Investments, the financial services firm that administers more than $7.4 trillion in assets, the average 401(k) plan balance reached $106,000 in the second quarter of 2019.

  • 42% of people say this is why they aren't investing in the stock market
    Business
    Yahoo Finance

    42% of people say this is why they aren't investing in the stock market

    A recent JPMorgan Chase survey of about 1,200 investors and non-investors says it boils down to liquidity. The survey found that 42% of those who weren't investing yet were staying out of the stock market because they believed they didn't have enough money to invest. Kelli Keough, digital wealth management head at JPMorgan Chase, tells Yahoo Finance's “The First Trade” non-investors, those who are not in the stock market, say it's a struggle to save enough money to invest.

  • The 10 Best Value Stocks to Own in 2020
    Business
    InvestorPlace

    The 10 Best Value Stocks to Own in 2020

    The past five years have not been good for buyers of value stocks. Overall, value stocks have been underperforming their growth brethren since at least 2007. Arnott went on to suggest that if the economy slows down at some point in 2020, growth stocks will have nowhere to hide — leaving value stocks to attract the lion's share of the buyers.

  • What interest rates dating back to 1311 tell us about today’s global economy
    Business
    Quartz

    What interest rates dating back to 1311 tell us about today’s global economy

    Interest rates sure are weird these days. Five central banks currently hold policy rates negative; several are dabbling with unconventional bond-buying. The one bank that tried to raise them, the Federal Reserve, found itself back cutting rates within a year.

  • Should Your Required Minimum Distribution Be in Cash?
    Business
    Investopedia

    Should Your Required Minimum Distribution Be in Cash?

    Should you take your RMD by getting the cash or transferring the stock to another account? According to Michael J. Garry, managing member and chief compliance officer at Yardley Wealth Management, it doesn't matter for tax purposes. "There is usually little, if any, tax efficiency added by taking in-kind distributions instead of cash.

  • 3 “Strong Buy” Biotech Stocks That Can Inject a Healthy Dose of Upside
    Business
    TipRanks

    3 “Strong Buy” Biotech Stocks That Can Inject a Healthy Dose of Upside

    To watch Selvaraju's track record, click here) The Street appears equally confident in IMMU's future potential; 4 Buy ratings add up to a Strong Buy consensus rating. With an average price target of $28, the analysts believe Immunomedics can add 47% to its share price over the coming year. See Immunomedics stock analysis on TipRanks) Revance Therapeutics (RVNC) After a disappointing 2019, which saw Revance's share price drop by more than 18%, the neuromodulator-focused biotech has started 2020 with a bang; Revance stock is up by 38% year-to-date.

  • Top Tips to Reduce Required Minimum Distributions
    Business
    Investopedia

    Top Tips to Reduce Required Minimum Distributions

    Holders of individual retirement accounts (IRAs), 401(k)s, and other qualified retirement accounts are required to take distributions from those accounts beginning at age 72. These required minimum distributions (RMDs) force the account holder to take a taxable distribution based on the account balance at the end of the prior year and their age. The logic behind requiring distributions is that the government wants to collect taxes for all of that tax-deferred growth (as well as the original tax-deferral) and that the investor will likely be in a lower tax bracket during retirement.

  • Business
    Benzinga

    Barron's Picks And Pans: Apple, Boeing, Disney, Tesla And More

    Barron's Roundtable panelist Rupal Bhansali's makes a case that Apple Inc. NYSE: AAPL) is disadvantaged on many fronts and trying to play catch-up in "Time to Short Apple, Says Rupal Bhansali. Yes, Short Apple."

  • America Is Awash With Natural Gas and It’s About to Get Worse
    Business
    Bloomberg

    America Is Awash With Natural Gas and It’s About to Get Worse

    One chilly day in October, President Donald Trump boarded Air Force One and flew to Pennsylvania to hail one of the state's most important industries -- not coal, but natural gas. Trump spoke an industry event of the “astonishing increase” in shale gas production. The Appalachian region has spearheaded a historic expansion, turning the U.S. into the world's biggest producer while slashing prices for consumers and sounding the death-knell for domestic coal.

  • Dramatic video, truck crashes offroad near trooper
    U.S.
    Associated Press Videos

    Dramatic video, truck crashes offroad near trooper

    Officials in the US state of Iowa are urging people to use caution and stay indoors if possible as blizzard conditions continued to wreak havoc in northern and central parts of the state on Saturday. Jan.

  • Business
    Barrons.com

    Big Buys of Intel, AT&T, and Facebook Stock by Norway’s Biggest Bank

    Norway's largest financial-services group, DnB, made some big changes in its U.S.-traded stock investments in the last quarter of 2019. DnB more than tripled its investment in (INTC) stock (ticker: INTC) and cut its investment in rival (AMD) (AMD) nearly in half. The bank also bought substantially more (T) stock (T) and (FB) stock (FB).

  • Why State Street’s $20 Billion Dividend ETF Must Drop Two Stocks
    Business
    Bloomberg

    Why State Street’s $20 Billion Dividend ETF Must Drop Two Stocks

    State Street's SPDR S&P Dividend ETF will likely have to sell off large stakes in Meredith Corp. and Tanger Factory Outlet Centers Inc. Bloomberg Intelligence's James Seyffart has the details on "Bloomberg Markets."

  • Value stocks are making a comeback, and here’s how to get in early
    Business
    MarketWatch

    Value stocks are making a comeback, and here’s how to get in early

    I believe that is unlikely to continue,” says Joel Greenblatt, the co-chief investment officer at Gotham Funds. was the worst year since 1999 for the strategy of buying cheap stocks and shorting expensive stocks (the top quintile for each), Greenblatt says. The last time this strategy experienced such extremely poor results, value put in three great years of performance, from 2000-2002.

  • 3 Monster Growth Stocks That Can Rip Higher in 2020
    Business
    TipRanks

    3 Monster Growth Stocks That Can Rip Higher in 2020

    The impressive share gains are bolstered by a strong financial performance. MTZ last reported earnings at the beginning of November, and easily beat the EPS forecasts and the year-ago numbers. For revenue, MTZ reported $2.02 billion, which missed the forecast but was still up 2% year-over-year.

  • 3 ETFs to Buy Instead of Popular Mutual Funds
    Business
    InvestorPlace

    3 ETFs to Buy Instead of Popular Mutual Funds

    To that end, investors in some popular mutual funds could be better suited making the switch into ETFs. For investors in tax-deferred or tax-free accounts, the switch is easy. For investors in taxable accounts, you need to weigh the potential hit from the switch.

  • Best Buy launches investigation into CEO Corie Barry
    Business
    American City Business Journals

    Best Buy launches investigation into CEO Corie Barry

    Best Buy Co. Inc. CEO Corie Barry is under investigation by the retailer's board after it received an anonymous letter alleging an inappropriate romantic relationship between Barry and another executive before she became CEO last year. It claimed that she had been romantically involved with former Best Buy Senior Vice President Karl Sanft in the period before she took over as the company's CEO, the newspaper said. Best Buy's board has hired law firm Sidley Austin LLP as part of the investigation.

  • Will you ‘feel pretty stupid’ holding cash? One trader revisits Ray Dalio’s laughable call and warns of a similar drop
    Business
    MarketWatch

    Will you ‘feel pretty stupid’ holding cash? One trader revisits Ray Dalio’s laughable call and warns of a similar drop

    Almost exactly two years ago, investing legend Ray Dalio turned heads with one of the worst short-term market calls in recent memory. The Bridgewater Associates founder, in an interview at the World Economic Forum back in January 2018, told investors that they were going to “feel pretty stupid” if they were holding cash as stocks climbed toward record highs. So, how stupid did they feel?

  • Why ‘irrationally bullish’ investors are getting nervous as the stock market races to uncharted territory
    Business
    MarketWatch

    Why ‘irrationally bullish’ investors are getting nervous as the stock market races to uncharted territory

    The Dow Jones Industrial Average (DJIA) traversed a milestone at 29,000, the S&P 500 index (SPX) followed with its own landmark turn above 3,300 and the Nasdaq Composite Index (COMP) is rallying like it is 1999. Another way to think about, the ferocity by which stocks have climbed in the first three weeks of this year, S&P 500 gains have already exceeded the 2020 estimates for nearly half the 18 analysts surveyed by MarketWatch. “We stay irrationally bullish until peak positioning & peak liquidity incite [a] spike in bond yields & 4-8% equity correction,” wrote analysts at Banc of America Securities on Friday in a weekly research report on the state of the market.

  • Boeing Stock Could Run to $400 Under New CEO David Calhoun
    Business
    InvestorPlace

    Boeing Stock Could Run to $400 Under New CEO David Calhoun

    Worse, for the first time in three decades, Boeing had a negative net number of airplane orders. On top of that, American Airlines (NASDAQ:AAL) said it would keep the 737 Max out of commission until June 2020, according to Fortune contributor Erik Sherman. This all comes just weeks after Boeing fired CEO Denis Muilenberg, and after the Federal Aviation Administration's Stephen Dickson said there was no way the FAA would allow the planes to fly again in 2019.

  • Is There Now An Opportunity In Cisco Systems, Inc. (NASDAQ:CSCO)?
    Business
    Simply Wall St.

    Is There Now An Opportunity In Cisco Systems, Inc. (NASDAQ:CSCO)?

    Today I will analyse the most recent data on Cisco Systems's outlook and valuation to see if the opportunity still exists. Is Cisco Systems still cheap? According to my valuation model, Cisco Systems seems to be fairly priced at around 3.7% below my intrinsic value, which means if you buy Cisco Systems today, you'd be paying a reasonable price for it.

  • Ocasio-Cortez sums up inequality in 5 words after Dow breaks through 29,000
    Business
    MarketWatch

    Ocasio-Cortez sums up inequality in 5 words after Dow breaks through 29,000

    That's “inequality in a nutshell,” according to Rep. Alexandria Ocasio-Cortez, who fired off those words in a tweet response to NBC's coverage of a fresh high for the Dow Jones Industrial Average (DJIA)on Friday. The New York Democrat was making the point that while the blue-chip index rallied more than 20% last year, U.S. average hourly earnings gained less than 3%. And since stocks are generally held by those with higher wealth levels, the data would support her “rich getting richer” stance.

  • Business
    Oilprice.com

    China’s Cheap Electric Vehicles Could Disrupt Global Markets

    While Western automakers race to capture market share in the world's biggest electric car market, China, hundreds of Chinese electric vehicle (EV) makers have sprung up in recent years to snag a piece of the EV pie too. Government support to the Chinese EV industry and China's ambitions to have new energy vehicles (NEVs) sales account for a quarter of car sales in 2025 means that the Chinese authorities want the EV industry in the country to flourish—and some think this ambitious target would require both Western and Chinese EV makers. Western analysts, however, warn that a Chinese EV oversupply could lead to cut-price exports of China's electric cars, potentially distorting and pressuring the auto industries in other countries, and potentially setting the stage for the next U.S.-China trade war front—electric vehicles.

  • Should You Be Excited About Apple Inc.'s (NASDAQ:AAPL) 61% Return On Equity?
    Business
    Simply Wall St.

    Should You Be Excited About Apple Inc.'s (NASDAQ:AAPL) 61% Return On Equity?

    With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. To keep the lesson grounded in practicality, we'll use ROE to better understand Apple Inc. (NASDAQ:AAPL). Over the last twelve months Apple has recorded a ROE of 61%.

  • Tesla Hits All-Time High Before Being Downgraded: Where to Now?
    Business
    TipRanks

    Tesla Hits All-Time High Before Being Downgraded: Where to Now?

    So, where is Tesla headed? This week, analysts have been throwing the hat in, offering takes on the electric vehicle company from all possible angles, with the most recent rating being a downgrade. In this article, we'll take a look at three different ratings from the analysts.

  • Is iQiyi Stock Worth $15 or $30?
    Business
    InvestorPlace

    Is iQiyi Stock Worth $15 or $30?

    However, at this point, it's hard to know if the move indicates that IQ stock is worth $30 per share or $15 per share. Here's a look at both sides of the argument. IQ Stock Is Worth $30 Per Share The lack of movement by the company's stock since the partnership was announced suggests that investors aren't reading too much into the situation.